Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies

X Wu, M Xu, M Geng, S Chen, PJ Little, S Xu… - Signal transduction and …, 2023 - nature.com
The ever-increasing prevalence of noncommunicable diseases (NCDs) represents a major
public health burden worldwide. The most common form of NCD is metabolic diseases …

[HTML][HTML] PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives

H Inuzuka, J Liu, W Wei, AH Rezaeian - Acta materia medica, 2022 - ncbi.nlm.nih.gov
Neurodegenerative diseases (NDs) are characteristic with progression of neuron
degeneration, resulting in dysfunction of cognition and mobility. Many neurodegenerative …

Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)

J Chotitumnavee, Y Yamashita, Y Takahashi… - Chemical …, 2022 - pubs.rsc.org
We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective
degradation of histone deacetylase 8 (HDAC8). The PROTAC induced degradation of …

Targeting undruggable transcription factors with PROTACs: advances and perspectives

Y Li, J Song, P Zhou, J Zhou, S Xie - Journal of Medicinal …, 2022 - ACS Publications
Dysregulation of transcription factors has been implicated in a variety of human diseases.
However, these proteins have traditionally been regarded as undruggable and only a …

PROTACs: Novel tools for improving immunotherapy in cancer

S Li, T Chen, J Liu, H Zhang, J Li, Z Wang, G Shang - Cancer Letters, 2023 - Elsevier
Posttranslational modifications (PTMs), such as phosphorylation, methylation, ubiquitination,
and acetylation, are important in governing protein expression levels. Proteolysis targeting …

TRIM proteins in hepatocellular carcinoma

K Lu, Y Pan, Z Huang, H Liang, Z Ding… - Journal of Biomedical …, 2022 - Springer
The tripartite motif (TRIM) protein family is a highly conserved group of E3 ligases with 77
members known in the human, most of which consist of a RING-finger domain, one or two B …

Ubiquitin–proteasome system as a target for anticancer treatment—an update

YJ Kim, Y Lee, H Shin, SA Hwang, J Park… - Archives of pharmacal …, 2023 - Springer
As the ubiquitin–proteasome system (UPS) regulates almost every biological process, the
dysregulation or aberrant expression of the UPS components causes many pathological …

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Q Li, L Zhou, S Qin, Z Huang, B Li, R Liu… - European Journal of …, 2023 - Elsevier
The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)

AL Saraswat, R Vartak, R Hegazy, A Patel, K Patel - Drug Discovery Today, 2023 - Elsevier
Highlights•PROTACs are novel class of molecules efficiently degrades pathogenic
protein.•Due to large hydrophobic structure, PROTACs are usually considered bRo5 …

Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy

RP Bhole, PR Kute, RV Chikhale, CG Bonde, A Pant… - Bioorganic …, 2023 - Elsevier
The technology known asPROTACs (PROteolysisTArgeting Chimeras) is a method of
protein degradation. Utilising bifunctional small molecules, the ubiquitin-proteosome system …